Posted by Michael Wonder on 02 Feb 2022
Equity in cancer drug access in the UK
1 February 2022 - In draft guidance published on 5 January 2022, NICE announced their decision not to recommend the use of olaparib for the treatment of patients with metastatic castration-resistant prostate cancer with BRCA1/2 mutations on the National Health Service—a decision that was met with surprise and disappointment.
Surprise because the drug was recommended for the same indication in patients in Scotland by the Scottish Medicines Consortium in October, 2021. And disappointment because the decision means that patients in England, Wales, and Northern Ireland might not have the same access to the drug.
